Timothy P. Walbert - Jun 1, 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Role
Chairman, President and CEO, Director
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Stock symbol
HZNP
Transactions as of
Jun 1, 2021
Transactions value $
-$2,296,204
Form type
4
Date filed
6/3/2021, 04:41 PM
Next filing
Jun 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Sale -$680K -7.48K -0.83% $91.00 893K Jun 1, 2021 Direct F1, F2, F3
transaction HZNP Ordinary Shares Sale -$1.62M -17.5K -1.96% $92.21 876K Jun 1, 2021 Direct F1, F4
holding HZNP Ordinary Shares 21K Jun 1, 2021 By Spouse F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.48 to $91.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.75 to $92.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Includes 1,049 ordinary shares of the Issuer acquired by the reporting person's spouse on June 1, 2021 pursuant to an employee stock purchase program.